42 research outputs found
Abundance of Pelagia noctiluca early life stages in the western Mediterranean Sea scales with surface chlorophyll
Pelagia noctiluca is the most successful and well-studied jellyfish in the Mediterranean Sea. This species tolerates a wide range of water temperatures and succeeds in low to medium food regimes, but factors driving its distribution and population dynamics remain poorly understood. Here we applied a multiscale analytical approach using survey data and a physical-biochemical coupled model to assess how environmental factors affect the 3-dimensional distribution and seasonal abundance of P. noctiluca early life stages. The surveys took place after the spring bloom, when warm water favors fecundity and growth, but food shortage limits the reproductive investment and early survival. We found that most early life stages of P. noctiluca remained above the shallow thermocline and upper mixed layer where temperature is warm. Their spatial distribution was positively correlated with surface chlorophyll concentration, and over 90% of the variation in interannual abundance was explained by basin-scale productivity in June. Warmer water during winter and spring seasons coupled with protracted spring blooms increase the population of P. noctiluca, and this explains the trend of increasing outbreaks observed in the western Mediterranean Sea over the past decades.Postprin
DATA AND INITIAL MODEL SET-UP FOR THE 2022 STOCK SYNTHESIS STOCK ASSESSMENT OF THE EASTERN ATLANTIC AND MEDITERRANEAN BLUEFIN TUNA
This document describes the data used for Stock Synthesis assessment for the Eastern Atlantic
and Mediterranean bluefin tuna. The initial model configuration, fleet definitions, selectivity
modeling and main parameterization are also outlined. The model runs from 1950 to 2020 and
is fit to length composition data and pair age-length data treated as conditional age-at-length.En prens
A global review of marine recreational spearfishing
24 pages, 5 figures, 2 tables, supplementary information https://doi.org/10.1007/s11160-023-09790-7.-- Data availability: The full list of papers used for the systematic review is available as a supplementary tableRecreational spearfishing is a fishing method that occurs globally, yet receives considerably less attention in the scientific literature relative to other recreational fishing methods, such as angling. Lack of scientific information on spearfishing may negatively affect the development and management of marine recreational fisheries. We conducted a systematic review of 102 peer-reviewed papers published between 1967 and 2022 pertaining to marine recreational spearfishing. Based on this literature review, we provide an overview of key insights across social, economic, and ecological dimensions of marine recreational spearfishing. While spearfishers represent less than 5% of marine recreational fishers, the participants are younger and may differ from recreational anglers in their motivations, with suggestions of increased well-being generated from a close connection with the sea during underwater fishing. Recreational spearfishers mostly target species of moderate to high levels of vulnerability that are mid to high trophic level carnivores. Though spearfishers can deliberately target larger individuals of exploited populations, this is not a generalizable pattern. Despite a growing body of research on the ecological impacts of marine recreational spearfishing, there is limited knowledge of these effects and their mechanisms across biological levels of organization (e.g., individual, population, community and ecosystem) compared with those of other fishing methods. Recreational spearfishers can contribute to advances in marine ecological knowledge, and inclusive participatory management could represent a key step towards transformative sustainable development of marine recreational spearfishing. Throughout the review, we identify gaps in the research and areas where future research is needed to better inform the socio-economic importance, ecosystem impacts and future management of marine recreational spearfishingVS was supported by a âJuan de la Cierva IncorporaciĂłnâ (IJC2018-035389-I), and he is now supported by a âRamĂłn y Cajalâ research fellowships (RYC2021-033065-I) granted by the Spanish Ministry of Science and Innovation. SV and PP are supported by the Xunta de Galicia (RECREGES I and II projects under Grants ED481B2014/034-0 and ED481B2018/017), Grupo de Referencia Competitiva GI-2060 AEMI, under Grant ED431C2019/11), and FundaciĂłn Biodiversidad, Ministerio para la TransiciĂłn EcolĂłgica y el Reto DemogrĂĄfico, Gobierno de España (SICORE and GT PMR projects). VJG received a postdoctoral grant (#2017/22273-0) from SĂŁo Paulo Research Foundation (FAPESP). MR would like to acknowledge Portuguese national funds from FCTâFoundation for Science and Technology through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020. MR would also like to acknowledge FCT funding through a postdoctoral grant (SFRH/BPD/116307/2016). JACCN thanks to Meros do Brasil Project sponsored by Petrobras. FJH is supported by a SÈr Cymru European Regional Development Fund Fellowship (80761-SU-135). RA was supported by the German Federal Ministry of Education and Research (Grants 01LC1826E and 033W046A). ML is supported by the Agencia Nacional de InvestigaciĂłn e InnovaciĂłn (ANII, POS_EXT_2020_1_165362). This work acknowledges the âSevero Ochoa Centre of Excellenceâ accreditation (CEX2019-000928-S). [...] Open Access funding provided thanks to the CRUE-CSIC agreement with Springer NaturePeer reviewe
Recommended from our members
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
PURPOSE: Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility. METHODS: In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using gene-based tests (SKAT-O). RESULTS: The most significant associated gene in the discovery cohort was ETFB (electron transfer flavoprotein beta subunit) involved in mitochondrial ÎČ-oxidation and ATP production (PÂ =Â 4.16Â ĂÂ 10-4) and this association was replicated in an independent set of anthracycline-treated cancer patients (PÂ =Â 2.81Â ĂÂ 10-3). Within ETFB, we found that the missense variant rs79338777 (p.Pro52Leu; c.155CÂ >Â T) made the greatest contribution to the observed gene association and it was associated with increased risk of chronic AIC in the two cohorts separately and when combined (OR 9.00, PÂ =Â 1.95Â ĂÂ 10-4, 95% CI 2.83-28.6). CONCLUSIONS: We identified and replicated a novel gene, ETFB, strongly associated with chronic AIC independently of age at tumor onset and related to anthracycline-mediated mitochondrial dysfunction. Although experimental verification and further studies in larger patient cohorts are required to confirm our finding, we demonstrated that exome array data analysis represents a valuable strategy to identify novel genes contributing to the susceptibility to chronic AIC
Genetic mechanisms of critical illness in COVID-19.
Host-mediated lung inflammation is present1, and drives mortality2, in the critical illness caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development3. Here we report the results of the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units. We have identified and replicated the following new genome-wide significant associations: on chromosome 12q24.13 (rs10735079, PÂ =Â 1.65Â ĂÂ 10-8) in a gene cluster that encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3); on chromosome 19p13.2 (rs74956615, PÂ =Â 2.3Â ĂÂ 10-8) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs2109069, PÂ =Â 3.98Â ĂÂ Â 10-12) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1 (rs2236757, PÂ =Â 4.99Â ĂÂ 10-8) in the interferon receptor gene IFNAR2. We identified potential targets for repurposing of licensed medications: using Mendelian randomization, we found evidence that low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease; and transcriptome-wide association in lung tissue revealed that high expression of the monocyte-macrophage chemotactic receptor CCR2 is associated with severe COVID-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammatory organ damage in COVID-19. Both mechanisms may be amenable to targeted treatment with existing drugs. However, large-scale randomized clinical trials will be essential before any change to clinical practice
Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study
Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ℠0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (â„18 years) with S aureus bacteraemia who had received â€96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (nâ=â143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (nâ=â152), or no hydrocortisone (nâ=â108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (nâ=â137), shock-dependent (nâ=â146), and no (nâ=â101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 nonâcritically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (nâ=â257), ARB (nâ=â248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; nâ=â10), or no RAS inhibitor (control; nâ=â264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ supportâfree days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ supportâfree days among critically ill patients was 10 (â1 to 16) in the ACE inhibitor group (nâ=â231), 8 (â1 to 17) in the ARB group (nâ=â217), and 12 (0 to 17) in the control group (nâ=â231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ supportâfree days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
Stock-environment recruitment analysis for Namibian Cape hake (Merluccius capensis)
10 pĂĄginas.The factors modulating recruitment success of Cape hake Merluccius capensis in Namibian waters are still unresolved. In this study, we used generalised additive models, regression tree analysis and the conventional Ricker model to examine the effect of environmental indices and spawning stock biomass (SSB) on hake recruitment success for the period 1984â2012. Results indicated that upwelling strength explained 51% of the recruitment variability, whereas SSB had no significant influence. The effect of SSB on recruitment only became significant when combined with upwelling strength, explaining 89% of the recruitment variability. SSB influenced recruitment during periods of strong upwelling. Optimal conditions for hake recruitment were associated with moderate upwelling strength. Low and high upwelling intensities reduced recruitment success. Our results are consistent with those of other studies suggesting a significant influence of environmental conditions on recruitment at a low spawning stock level. Our study highlights the importance of assessing the combined non-linear effects of both biotic and abiotic factors on hake recruitment.Peer reviewe